Volume 4, Issue 4, July 2018, Page: 31-34
Current and Next Generation Vaccines Against Influenza
Kazuyoshi Kaminaka, Research Department, Kikuchi Research Center, KM Biologics Co., Ltd., Kumamoto, Japan
Chikateru Nozaki, Department of Medical Technology, Kumamoto Health Science University, Kumamoto Japan
Received: Nov. 12, 2018;       Accepted: Nov. 28, 2018;       Published: Dec. 25, 2018
DOI: 10.11648/j.ijpc.20180404.11      View  193      Downloads  117
Abstract
Influenza is an infectious disease. In order to overcome various infectious diseases, many vaccines have been developed so far. Influenza vaccines have played an important role in prevention and control of influenza. However, current influenza vaccines are not perfect. Current influenza vaccines are produced by anticipating influenza viruses that may occur in annual epidemics or pandemics because influenza viruses have characteristic of antigen mutations. Furthermore, current subcutaneous or intramuscular inoculation of vaccine cannot sufficiently induce IgA that plays an important role in defending the entry of pathogens from the mucosa. In order to overcome the drawbacks of these current influenza vaccines, next generation vaccines are under investigation. One candidate is universal influenza vaccine using the antigens that are conserved among influenza virus strains. Another one is mucosal vaccine that can induce IgA on the mucosa of the upper respiratory tract. Here current and next generation influenza vaccines are described.
Keywords
Influenza, Hemagglutinin (HA), Universal Vaccine, Matrix Protein2 (M2), Mucosa
To cite this article
Kazuyoshi Kaminaka, Chikateru Nozaki, Current and Next Generation Vaccines Against Influenza, International Journal of Pharmacy and Chemistry. Vol. 4, No. 4, 2018, pp. 31-34. doi: 10.11648/j.ijpc.20180404.11
Copyright
Copyright © 2018 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Paules C, Subbarao K. Influenza. Lancet. 2017 Aug 12; 390(10095): 697-708.
[2]
Short KR, Kedzierska K, van de Sandt CE. Back to the Future: Lessons Learned From the 1918 Influenza Pandemic. Front Cell Infect Microbiol.2018 Oct 8;8:343.
[3]
Hegde NR. Cell culture-based influenza vaccines: A necessary and indispensable investment for the future. Hum Vaccin Immunother. 2015;11(5):1223-34.
[4]
Bouvier NM. The Future of Influenza Vaccines: A Historical and Clinical Perspective. Vaccines (Basel). 2018 Aug 30; 6(3).
[5]
Sano K, Ainai A, Suzuki T, Hasegawa H. The road to a more effective influenza vaccine: Up to date studies and future prospects. The road to a more effective influenza vaccine: Vaccine. 2017 Sep 25; 35(40): 5388-5395.
[6]
Hayden FG, Sugaya N, Hirotsu N, Lee N, de Jong MD, Hurt AC, Ishida T, Sekino H, Yamada K, Portsmouth S, Kawaguchi K, Shishido T, Arai M, Tsuchiya K, Uehara T, Watanabe A; Baloxavir Marboxil Investigators Group. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. N Engl J Med. 2018 Sep 6; 379(10): 913-923.
[7]
Barberis I, Myles P, Ault SK, Bragazzi NL, Martini M. History and evolution of influenza control through vaccination: from the first monovalent vaccine to universal vaccines. J Prev Med Hyg. 2016 Sep; 57(3): E115-E120.
[8]
Ziegler T, Mamahit A, Cox NJ. 65 years of influenza surveillance by a World Health Organization-coordinated global network. Influenza Other Respir Viruses. 2018 May 4.
[9]
Kim H, Webster RG, Webby RJ. Influenza Virus: Dealing with a Drifting and Shifting Pathogen. Viral Immunol. 2018 Mar; 31(2): 174-183.
[10]
Manini I, Trombetta CM, Lazzeri G, Pozzi T, Rossi S, Montomoli E. Manini I, Trombetta CM, Lazzeri G, Pozzi T, Rossi S, Montomoli E. Egg-Independent Influenza Vaccines and Vaccine Candidates. Vaccines (Basel). 2017 Sep; 5(3): 18.
[11]
Milián E, Kamen AA. Current and emerging cell culture manufacturing technologies for influenza vaccines. Biomed Res Int. 2015; 2015: 504831.
[12]
Ehrlich HJ, Berezuk G, Fritsch S, Aichinger G, Singer J, Portsmouth D, Hart MK, El-Amin W, Kistner O, Barrett PN. Clinical development of a Vero cell culture-derived seasonal influenza vaccine. Vaccine. 2012 Jun 19;30(29):4377-86..
[13]
Doroshenko A1, Halperin SA. Trivalent MDCK cell culture-derived influenza vaccine Optaflu (Novartis Vaccines). Expert Rev Vaccines. 2009 Jun;8(6):679-88.
[14]
Pau MG, Ophorst C, Koldijk MH, Schouten G, Mehtali M, Uytdehaag F. The human cell line PER.C6 provides a new manufacturing system for the oduction of influenza vaccines. Vaccine. 2001 Mar 21;19(17-19):2716-21.
[15]
Cox MM, Patriarca PA, Treanor J. FluBlok, a recombinant hemagglutinin influenza vaccine. Influenza Other Respir Viruses. 2008 Nov; 2(6): 211-9.
[16]
Margolin E, Chapman R, Williamson AL, Rybicki EP, Meyers AE. Production of complex viral glycoproteins in plants as vaccine immunogens. Plant Biotechnol J. 2018 Sep; 16(9): 1531–1545.
[17]
Pillet S, Aubin É, Trépanier S, Bussière D, Dargis M, Poulin JF, Yassine-Diab B, Ward BJ, Landry N. A plant-derived quadrivalent virus like particle influenza vaccine induces cross-reactive antibody and T cell response in healthy adults. Clin Immunol. 2016 Jul; 168: 72-87.
[18]
Fiers W, De Filette M, El Bakkouri K, Schepens B, Roose K, Schotsaert M, Birkett A, Saelens X. M2e-based universal influenza A vaccine. Vaccine. 2009 Oct 23; 27(45): 6280-3.
[19]
Rappazzo CG, Watkins HC, Guarino CM, Chau A, Lopez JL, DeLisa MP, Leifer CA, Whittaker GR, Putnam D. Recombinant M2e outer membrane vesicle vaccines protect against lethal influenza A challenge in BALB/c mice. Vaccine. 2016 Mar 4;34(10):1252-8.
[20]
Kolpe A, Schepens B, Fiers W, Saelens X. M2-based influenza vaccines: recent advances and clinical potential. Expert Rev Vaccines. 2017 Feb; 16(2): 123-136.
[21]
Matsui M1, Kohyama S, Suda T, Yokoyama S, Mori M, Kobayashi A, Taneichi M, Uchida T. A CTL-based liposomal vaccine capable of inducing protection against heterosubtypic influenza viruses in HLA-A*0201 transgenic mice. Biochem Biophys Res Commun. 2010 Jan 15; 391(3): 1494-9.
[22]
Boyaka PN. Inducing Mucosal IgA: A Challenge for Vaccine Adjuvants and Delivery Systems. J Immunol. 2017; 199: 9-16.
[23]
Ren ST, Zhang XM, Sun PF, Sun LJ, Guo X, et al. Intranasal Immunization Using Mannatide as a Novel Adjuvant for an Inactivated Influenza Vaccine and Its Adjuvant Effect Compared with MF59. PLoS One. 2017 Jan 4; 12(1): e0169501.
[24]
Suzuki T, Ainai A, Hasegawa H. Functional and structural characteristics of secretory IgA antibodies elicited by mucosal vaccines against influenza virus. Vaccine. 2017 Sep 18; 35(39): 5297-5302.
[25]
Lee YT, Ko EJ, Lee Y, Kim KH, Kim MC, Lee YN, Kang SM. Intranasal vaccination with M2e5x virus-like particles induces humoral and cellular immune responses conferring cross-protection against heterosubtypic influenza viruses. PLoS One. 2018 Jan 11; 13(1).
Browse journals by subject